Research Paper
Lorcaserin hydrochloride (LOR) is an antiobesity (selective serotonin 2c receptor agonist), off-white to white powder, which is freely soluble in water, methanol, acetonitrile and dimethyl sulphoxide having log P value of 2.56 and pKa of 9.53. LOR is not official in IP, BP and USP and is available as 10 mg tablets.
A number of analytical methods were reported in literature to analyse LOR in tablet formulation. A liquid chromatography-electro spray ionization-tandem mass spectrometry (LC-ESI-MS/MS) [1] method was reported for in vivo and in vitro pharmacological characterization of LOR. Also a chiral LC-MS/MS method for the separation and quantitation of lorcaserin and its S-enantiomer has been reported [2] . Despite of the fact that various analytical methods are available for the estimation of lorcaserin, no solid phase extraction based bioanalytical high-performance liquid chromatography (SPE HPLC) method was available in the literature to the best of our knowledge. Thus, the main aim of the study was to develop a SPE HPLC method for the determination of LOR in plasma and its application to rat pharmacokinetic study. Metoprolol (MET) was used as internal standard (IS) for bioanalytical method development. MET is an antihypertensive agent and having solubility in water and official in IP, BP and USP having log P value of 1.88 and pKa of 9.67. plasma was procured from Suraktam Blood Bank, Vadodara. The liquid chromatographic system was of Shimadzu, Mumbai and consisting of following components an isocratic pump, variable wavelength programmable UV/Vis detector, a manual injection facility with 20 μl fixed loop. The chromatographic analysis was performed using Spinchrom software on a Phenomenax-RP-18 column (250×4.6 mm, 5 µm particle size). In addition, an electronic balance (Shimadzu AX120ELB300), a pH meter (Lab India Pico+), sonicator (Spectra Lab, Selec XT 543), hot air oven (SK Industries), solid phase extractor (Orochem, Ezypress HT48), vortex shaker (SPINIX), membrane filter 0.22 micron (Pall Lifesciences, Ultipor Nylon), deep freezer (EIE Instruments), micropipette (Tarsons, accupipete), SPE cartridges (Phenomenex, Oasis HLB Cartridges), refrigerated centrifuge (Remi), refrigerator (Godrej, Pantacool) were used in this study. 
Preparation of mobile phase buffer:
About 10 mM phosphate buffer was prepared by dissolving 0.136 g of potassium dihydrogen orthophosphate in sufficient water to produce 100 ml.
The pH was adjusted to 3 using orthophosphoric acid. This buffer was filtered through 0.22 μ membrane filter and stored at ambient temperature.
Preparation of mobile phase:
Appropriate volumes of phosphate buffer (pH 3, adjusted with orthophosphoric acid), acetonitrile and methanol were transferred into a reagent bottle, mixed thoroughly, sonicated for 5 min and filtered through 0.22 µm membrane filter and used as mobile phase. The HPLC analysis was performed on reversed-phase HPLC system with isocratic elution mode using a mobile phase of phosphate buffer:acetonitrile:methanol (65:20:15 v/v/v) on Phenomenex Luna C 18 column (250×4.6 mm, 5 µm particle size) with 1 ml/min flow rate at 222 nm using UV detector.
Stock solutions of LOR and MET (1000 ppm):
About 10.8 mg of LOR hemihydrate (10.8 mg LOR hemihydrates is equivalent to 10 mg LOR) was weighed accurately, transferred into a 10 ml volumetric flask, dissolved in double distilled water and the volume made up to the mark to obtain the LOR stock solution.
About 10 mg of MET (IS) was weighed accurately, transferred to a 10 ml volumetric flask, dissolved in double distilled water and the volume was made up to the mark to obtain a MET stock solution.
Calibration standards for LOR:
Appropriate aliquots of LOR stock solution were taken in different 6 ml volumetric flasks and diluted up to the mark with mobile phase to obtain final concentrations of 10-60 μl/ml. To appropriate aliquots of calibration standards, 0.1 ml of 400 ppm IS was spiked and the final volume of 2 ml was made up with plasma to obtain final concentration of 500-3000 ng/ml. The linearity range was selected on the basis of reported peak plasma concentration (C max = 789 ng/ml) from literature.
To appropriate aliquots of calibration standards, 0.1 ml of 400 ppm IS was spiked and the final volume of 2 ml was made up with plasma to obtain final concentration of 500 ng/ml as lower limit of quantification control, 1000 ng/ml as low quality control, 2000 ng/ml as medium quality control (MQC), 3000 ng/ml as high quality control (HQC).
Bioanalytical method [3-6] :
Mobile phase trials were taken on unextracted samples. Also trials for selection of appropriate IS were taken in which screening was done on the basis of structural resemblance, log P value, pKa value and availability. Chromatographic trials for bisoprolol fumarate and MET succinate were undertaken with conditions described earlier in which MET succinate gave good peak as shown in Table 1 . [7, 8, 9] :
Method validation
The optimized method was validated as per the recommendations of USP [10, 11] and ICH [12, 13] for the parameters like accuracy, linearity, precision, detection limit, quantitation limit and robustness. Recovery of LOR in plasma was evaluated by comparing the mean peak responses of at least six injections of each low, medium and HQC sample, prepared in plasma, to mean peak responses of non-spiked samples prepared in elution solvent and external spiked matrix extracted sample. Recovery of IS in plasma was evaluated by comparing the mean peak responses of at least six MQC samples, prepared in plasma, to mean peak responses of non-spiked samples prepared in elution solvent and external spiked matrix extracted sample, replicates of aqueous samples of LOR. The mean standard deviation and % coefficient of variation (CV) for the peak area ratio and for the retention time of analyte and IS were calculated. Specificity and selectivity was carried out using six plasma samples. Blank (without IS) and zero sample (with IS) were analysed. The linearity of the method was determined over calibration range of 500 to 3000 ng/ml (Table 2) . Calibration standards were prepared by spiking known concentration of LOR working standard solution. A linearity curve containing six non-zero concentrations was analysed ( fig. 1 ). Back-calculated the concentrations of each level and plot the graph of back-calculated concentration against drug area ratio. The slope, y-intercept and correlation coefficient curve were calculated by suitable linear regression analysis as stated in Table 3 . Accuracy and precision was measured on the samples spiked with known amounts of the analyte. Accuracy and precision were determined by replicate analysis of six determinations of low, medium and HQC sample, which covers the calibration range. Precision is expressed as the % CV. The accuracy and precision were evaluated as within batch and between-batch [14] .
Bench top stability was performed at MQC level. Three replicates of MQC were withdrawn from deep freezer and were kept at room temperature for 12 h. These samples were preferred as stability samples after 12 h, prepared fresh samples of MQC concentrations of LOR in three replicates. These samples were referred as fresh or comparison samples. The freeze and thaw stability of analyte was determined after three freeze thaw (FT) cycles. The three sets of MQC samples were stored at -70±5 and subjected to three FT cycles at interval of 24 h. After the completion of three cycles of 12 to 24 h, the samples were analysed. Stability of samples was compared against freshly prepared samples.
The stability of LOR and IS in the stock solution were determined at room temperature for 7 h. Stock solution stability was performed by analysing three replicates of aqueous solutions prepared from freshly weighed stock solution against three replicates of aqueous solution prepared from aliquots of analyte and IS stored at room temperature for 7 h. The stability of LOR and IS in the stock solution were determined at 2-8° after 5 d. Refrigerated stock solution stability was performed by analysing three replicates of aqueous solution prepared from freshly weighed stock solution against three replicates of aqueous solution prepared from aliquots of analyte and IS stored at 2-8° after 5 d (stability samples; Table 4 ).
Pharmacokinetic studies:
The pharmacokinetic study was carried out in male Sprague Dawley rats. The six healthy animals were selected for the study. The animals were fasted overnight (~14 h) and had free access to water throughout the experimental period. LOR was administered by oral gavage at a dose of 10 mg/kg, as solution of drug in water. Blood samples (0.5 ml) were collected from the retro orbital plexus sinus at designated time points (0.25, 0.5, 1, 2, 3 and 4 h) into micro centrifuge tubes containing 100 μl of heparin. Plasma was harvested by centrifuging the blood using cold centrifuge compufuge at 3000 rpm for 10 min. Plasma (300 μl) samples were spiked with IS and processed same as standards as described above.
RESULTS AND DISCUSSION
Sample preparation technique used for the study plays a significant role with respect to bionalytical samples [15] [16] [17] [18] [19] [20] . It is essential to reduce the effect of the biological and buffer matrix. Sample preparation is applied to remove interfering compounds. As a bonus, analytes can be concentrated during the extraction processes. Sample preparation procedure is tedious and time consuming. However, the cleanliness of the samples affects The optimized SPE method parameters used for the study included Orochem SPE cartridge, sample pretreatment by 0.5 ml plasma sample+0.5 ml water (sample dilution, 1:2) conditioning with 0.5 ml methanol, equilibrating with 0.5 ml water, loading of 0.5 ml pre-treated sample, washing with 0.5 ml water, drying with nitrogen purging for 1-2 min and finally eluting with 0.5 ml methanol.
The extracted samples were retrieved from pre-labelled sample tubes stored in deep freezer at -20° and were pre-treated prior to extraction and then subjected to SPE. The extracted samples were subjected to HPLC. For development of analytical method for the estimation of LOR by RP HPLC, various chromatographic trials were taken. The various factors considered were flow rate, mobile phase composition, wavelength maxima and pH of mobile phase. The factors were varied on one factor at time basis [21] [22] [23] [24] [25] [26] . In the HPLC method optimized on extracted samples, mobile phase consisted of phosphate buffer:methanol:acetonitrile (65:15:2, pH 3.0), at 1 ml/min flow rate, which gave two sharp, well-resolved peaks with minimum tailing factor for LOR and MET in human plasma as shown in fig. 2A . The retention times for LOR and MET were 7.19 and 5.14 min, respectively. UV overlain spectra of both LOR and MET showed that both drugs absorbed appreciably at 222 nm, so this wavelength was selected as the detection wavelength. The calibration curve for LOR was found to be linear over the range of 500-3000 ng/ml ( fig. 1 ). The data of regression analysis of the calibration curves is shown in Table 3 . The proposed method was successfully applied to the determination of LOR in biological matrix. The developed method was also found to be specific, since it was able to separate drug in the biological matrix.
The chromatogram presented in fig. 2B is of blank (unspiked) rat plasma sample extracted using SPE extraction procedure as optimized below. The chromatogram depicted in fig. 2C showed some small peaks, well separated from the drug peak, but in absence of standard metabolite or any definite chromatographic pattern, it was difficult to identify the metabolite peak. All these peaks did not interfere with the drug analysis. Fig. 3 depicted the changes in drug concentrations at various designated time points (0, 30, 60, 120, 180, 240, 300 min). The pharmacokinetic parameters were calculated with a non-compartmental model using Thermo Kinetica PK/PD analysis software (version 5.0 Thermo Fisher Scientific). The peak plasma concentration (C max ) and the corresponding time (T max )
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[mV] were directly obtained from the raw data. The other pharmacokinetic parameters were obtained using non compartment model. AUC total was calculated using mixed log linear model. The pharmacokinetic data is presented in Table 5 [27] [28] [29] .
From the results and discussions, it could be concluded that the method developed for the analysis of LOR in rat plasma is specific, accurate, precise and reproducible. The use of this method could enable the characterization of LOR and its pharmacokinetics after single oral dose without any interference from the metabolite. According to pharmacology and toxicology review by CDER, based on plasma profiles, overall pattern of metabolism in humans is most closely approximated the metabolite pattern seen in rats [30, 31] . The assay can therefore be easily extended to quantitate LOR in plasma for routine monitoring of plasma levels of LOR in laboratories. 
